6533b839fe1ef96bd12a634b
RESEARCH PRODUCT
LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC).
Dirk RadesRenato ReyesCordula PetersenNils HomannMarkus MoehlerJuergen DebusAnne L KranichKarsten RidwelskiClaus Belkasubject
CisplatinOncologyCancer ResearchPoor prognosismedicine.medical_specialtyCetuximabbusiness.industryLocally advancedPhases of clinical researchEsophageal cancermedicine.diseaselaw.inventionOncologyRandomized controlled triallawInternal medicinemedicinebusinessmedicine.drugdescription
4081 Background: Patients (pts) with LAEC have a poor prognosis; new therapies are required. A study showed the addition of Cet to RCT to be safe and effective for resectable EC [Ruhstaller et al, ...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 | Journal of Clinical Oncology |